Preclinical data presented at CIMT confirm combination potential of vididencel with current and upcoming CML treatments

What we doOur approachPipelineTechnologyPatient Stories
About usManagementBoardClinical Advisory BoardCareers
Newsroom
InvestorsPress releasesEvents

Back
Preclinical data presented at CIMT confirm combination potential of vididencel with current and upcoming CML treatments
 8:00:00 AM

Keep reading
Mendus AB (publ) has resolved to transfer own sharesRead